A pair of studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition highlight continuing ...

I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene ...

SAN DIEGO — Pfizer’s abrupt withdrawal of its sickle cell drug Oxybryta over safety concerns was called “tone deaf” during a ...

Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation and three poster ...

Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through ...

By Karen Roman ReAlta Life Sciences said it is presenting new data at the American Society of Hematology (ASH) Annual Meeting ...

presented new investigational combination data in an oral presentation at the 2024 American Society of Hematology (ASH) Meeting in San Diego, CA. Data from the investigator-sponsored study were ...

Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

Rasika Venkataraman, a third-year doctoral student working in the lab of Stanley C. Lee, PhD, at Fred Hutch Cancer Center, ...